Healthcare · Biotechnology
Price
$1.45
Market Cap
$21.0M
Employees
16
Beta
0.54
Avg Volume
131,390
CEO
Uttam Yashwant Patil
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer. ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. ABV-1505 is progressing through Phase II clinical studies for attention deficit hyperactivity disorder (ADHD). ABV-1703 has concluded its Phase I clinical trials for the treatment of pancreatic cancer. ABV-1702 has also finished Phase I clinical investigations for myelodysplastic syndromes. ABV-1601 is in Phase I/II clinical trials, aimed at alleviating depression in individuals with cancer. ABV-1701 Vitargus is in development to treat conditions such as retinal detachment or vitreous hemorrhage. ABVC BioPharma maintains strategic alliances, including a co-development arrangement with Rgene Corporation, alongside collaborative agreements with BioHopeKing Corporation and BioFirst Corporation. The company's headquarters are located in Fremont, California, and it operates as a subsidiary of YuanGene Corporation.
Runs with full report
Price Overview
Last updated: Jul 10, 2026 4:19am (just now)
Current data · timestamped when a report runs
$1.45
Change · Jul 10
-0.57 (-28.22%)
Day Range
$1.45 – $2.00
52-Week Range
$0.88 – $4.95
50-Day MA
$1.30
200-Day MA
$1.92
Volume
510,687.00
Share Structure
Outstanding
14,490,444.00
Float
13,417,397.00
Free Float
92.6%
High free float
— 92.6% of shares trade freely, ~7.4% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-3.72
Stock Price: $1.45
EPS (Diluted): -0.39
EPS (Diluted): -0.39
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
4.46
Stock Price: $1.45
Total Equity: $11.11M
Shares: 23,256,590
Total Equity: $11.11M
Shares: 23,256,590
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-2.57
Market Cap: $21.01M
Total Debt: $3.47M
Cash: $681,480
EBITDA: -$7.43M
Total Debt: $3.47M
Cash: $681,480
EBITDA: -$7.43M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$52.3M
Market Cap: $21.01M
Total Debt: $3.47M
Cash: $681,480
Total Debt: $3.47M
Cash: $681,480
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
0.00
Stock Price: $1.45
Revenue: $0.00
Shares: 23,256,590
Revenue: $0.00
Shares: 23,256,590
EV/Sales (Total value vs revenue — works when P/E can't)
API0.00
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
0.0%
Gross Profit: $0.00
Revenue: $0.00
Revenue: $0.00
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
0.0%
Operating Income: -$7.15M
Revenue: $0.00
Revenue: $0.00
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
0.0%
Net Income: -$7.91M
Revenue: $0.00
Revenue: $0.00
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-92.0%
Net Income: -$7.91M
Total Equity: $11.11M
Total Equity: $11.11M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-56.7%
Operating Income: -$7.15M
Tax Rate: -0.3%
Equity: $11.11M
Total Debt: $3.47M
Cash: $681,480
Tax Rate: -0.3%
Equity: $11.11M
Total Debt: $3.47M
Cash: $681,480
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
0.41
Current Assets: $2.50M
Current Liabilities: $6.16M
Current Liabilities: $6.16M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.31
Short-Term Debt: $1.87M
Long-Term Debt: $1.60M
Total Debt: $3.47M
Total Equity: $11.11M
Long-Term Debt: $1.60M
Total Debt: $3.47M
Total Equity: $11.11M
Rev/Share (Top-line per share)
Revenue / Shares Outstanding
—
Revenue: $0.00
Shares: 23,256,590
Shares: 23,256,590
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$0.48
Total Equity: $11.11M
Shares: 23,256,590
Shares: 23,256,590
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-0.13
Operating CF: -$2.99M
CapEx: $0.00
Shares: 23,256,590
CapEx: $0.00
Shares: 23,256,590
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $1.45
Stock Price: $1.45
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$7.91M
Net Income: -$7.91M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares ABVC against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jul 10, 2026 3:08am (1h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $355,797 | $969,783 | $152,430 | $509,589 | $0 |
| Cost of Revenue | $5,086 | $286,415 | $302,037 | $763 | $0 |
| Gross Profit | $350,711 | $683,368 | $-149,607 | $508,826 | $0 |
| Operating Expenses | $12.1M | $15.8M | $6.6M | $5.2M | $7.2M |
| Operating Income | -$11.7M | -$15.1M | -$6.8M | -$4.7M | -$7.2M |
| Net Income | -$12.8M | -$16.4M | -$7.8M | -$4.9M | -$7.9M |
| EBITDA | -$11.0M | -$15.2M | -$6.3M | -$4.3M | -$7.4M |
| EPS | $-5.10 | $-5.20 | $-1.80 | $-0.42 | $-0.39 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jul 10, 2026 3:08am (1h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $5.8M | $1.4M | $716,780 | $863,815 | $681,480 |
| Total Current Assets | $7.7M | $3.0M | $1.7M | $2.2M | $2.5M |
| Total Assets | $13.7M | $10.9M | $7.8M | $7.5M | $21.1M |
| Current Liabilities | $3.7M | $5.5M | $6.1M | $6.6M | $6.2M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $1.6M |
| Total Liabilities | $4.8M | $6.3M | $6.5M | $6.8M | $7.8M |
| Total Equity | $8.8M | $4.5M | $1.6M | $1.2M | $11.1M |
| Retained Earnings | -$38.5M | -$54.9M | -$64.0M | -$68.9M | -$76.9M |
Cash Flow (Annual)
Last updated: Jul 10, 2026 3:08am (1h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$7.6M | -$7.4M | -$4.2M | -$1.8M | -$3.0M |
| Capital Expenditure | $-17,503 | $-119,692 | $-21,201 | $5 | $0 |
| Free Cash Flow | -$7.6M | -$7.5M | -$4.2M | -$1.8M | -$3.0M |
| Acquisitions (net) | $-680,916 | -$1.6M | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $-7,320 | $0 |
| Net Change in Cash | $1.6M | -$5.2M | $-674,948 | $147,035 | $463,170 |
Analyst Estimates (Annual)
Last updated: Jul 10, 2026 3:08am (1h ago)| Metric | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Revenue |
$697,754 $248,963 – $1.1M
|
$14.5M $14.5M – $14.5M
|
$4.2M $4.2M – $4.2M
|
$35.3M $35.3M – $35.3M
|
| EBITDA |
$-697,754 -$1.1M – $-248,963
|
-$8.7M -$8.7M – -$8.7M
|
-$2.5M -$2.5M – -$2.5M
|
-$21.2M -$21.2M – -$21.2M
|
| Net Income |
-$23.3M -$23.3M – -$23.3M
|
-$102.3M -$102.3M – -$102.3M
|
-$107.0M -$107.0M – -$107.0M
|
$30.2M $30.2M – $30.2M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jul 10, 2026 3:08am (1h ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +172.6% | -84.3% | +234.3% | -100.0% |
| Gross Profit Growth | +94.9% | -121.9% | +440.1% | -100.0% |
| Operating Income Growth | -29.1% | +55.2% | +30.5% | -52.0% |
| Net Income Growth | -27.9% | +52.6% | +37.0% | -61.3% |
| EBITDA Growth | -38.5% | +58.3% | +31.4% | -71.1% |
Insider Trading (Recent)
Last updated: Jul 10, 2026 3:08am (1h ago)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2022-05-20 | Jiang Shuling | 0.00 | $0.00 | $0 | |
| 2021-08-02 | An Chihliang | 0.00 | $0.00 | $0 | |
| 2021-08-02 | Sakamoto Norimi | 0.00 | $0.00 | $0 | |
| 2021-08-02 | Odaira Yoshinobu | 0.00 | $0.00 | $0 | |
| 2021-08-02 | Jiang Tsung Shann | 0.00 | $0.00 | $0 | |
| 2021-08-02 | Miao Shin-Yu | 0.00 | $0.00 | $0 | |
| 2021-11-08 | Tseng Shih-Chen | 0.00 | $0.00 | $0 | |
| 2021-08-02 | Jiang Eugene | 0.00 | $0.00 | $0 | |
| 2021-08-02 | Jiang Chang-Jen | 0.00 | $0.00 | $0 | |
| 2021-08-02 | King Chi-Hsin Richard | 0.00 | $0.00 | $0 | |
| 2021-08-02 | Chou Yen-Hsin | 0.00 | $0.00 | $0 | |
| 2021-08-02 | Doong Howard | 0.00 | $0.00 | $0 | |
| 2021-08-02 | Jiang Tsang Ming | 0.00 | $0.00 | $0 | |
| 2015-09-08 | Lazar Shulamit | 0.00 | $0.00 | $0 | |
| 2012-01-27 | Stolz Kevin Patrick | A-Award | 6,250.00 | $0.00 | $0 |
| 2011-05-25 | Krotine Frank Thomas | A-Award | 300,000.00 | $0.20 | $60,000 |
| 2011-05-11 | Stolz Kevin Patrick | A-Award | 50,000.00 | $0.20 | $10,000 |
| 2011-05-11 | IANNOTTI DANIEL V | A-Award | 300,000.00 | $0.20 | $60,000 |
| 2011-05-11 | Crockett Robert G | A-Award | 1,800,000.00 | $0.20 | $360,000 |
| 2011-05-11 | Ramsey Sally Judith | A-Award | 2,100,000.00 | $0.20 | $420,000 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for ABVC — it's generated by the pipeline (
market-narrative step).
No community reviews yet for ABVC.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.397 · fd27f02b · 2026-07-09 18:28:55